Emerge Health


Posted 28-Oct-2019

Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI® in Australia and New Zealand

San Diego, California – September 30, 2019 - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty (“Emerge”) to register and commercialize Adamis’ SYMJEPI® (epinephrine) Injection products in Australia and New Zealand.

Under the terms of the agreement, Adamis will provide technical support to Emerge during the registration process, which could take more than a year. If successful, Adamis will begin supplying product to Emerge. Emerge will be responsible for the full registration, reimbursement, sales, marketing and distribution of SYMJEPI® in Australia and New Zealand (the “Territory”).

Once commercially launched, Adamis and Emerge will equally share net profits (as defined in the agreement) generated from sales of SYMJEPI® in the Territory. Based on its experience with the registration process in the Territory, Emerge does not anticipate that a commercial launch could occur before 2021.

Adamis hopes that Emerge will find a ready market for SYMJEPI® as Australia has among the highest allergy rates in the world. A study published in 2017 in the Journal of Allergy and Clinical Immunology indicates that, in Australia, 1 in 10 infants and 1 in 20 children aged 10-14 years have food allergies.

High rates of allergies typically result in higher incidences of anaphylaxis, and Australian hospital admissions for anaphylaxis have increased five-fold in the last 20 years. According to the Murdoch Children’s Research Institute in Victoria, Australia has one of the highest rates of hospital admissions for anaphylaxis in the developed world.

David J. Marguglio, Chief Business Officer of Adamis, stated, “We are very excited to be working with a great company like Emerge and see this as another important step toward our goal of making SYMJEPI® available to patients and caregivers around the world. We are also pleased that our first commercial partnership for SYMJEPI® outside the United States is for a territory we feel has a heightened need of a ready supply of epinephrine injection products.”

Chris Rossidis, Co-Founder and Head of Emerge's Commercial Operations added, “The prevalence of allergies and inconsistent availability of epinephrine injection products have combined to create a public health crisis in Australia. We hope that through our partnership with Adamis we may be able to ensure all patients have access to this important and potentially life-saving product.”

About Anaphylaxis

Anaphylaxis is a serious, sometimes life-threatening allergic reaction. The most common anaphylactic reactions are to foods, insect stings, medications and latex. Anaphylaxis requires immediate medical treatment, including an injection of epinephrine. The use of epinephrine injection products has grown as the risk of anaphylaxis and allergic reactions have become more widely understood.

About Emerge Health Pty

Emerge is an innovative, specialized pharmaceutical company focused on the marketing and sales of high-quality medicines in Australia and New Zealand. Emerge is dedicated to providing exceptional products and support to ensure they meet their customers' and partners' needs and priorities.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including respiratory disease, allergy and opioid overdose. The company’s SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products were approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis, and both were fully launched in the U.S. in July 2019.

Please refer to www.SYMJEPI.com for additional product information. Adamis is developing additional products, including a naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose, and a metered dose inhaler and dry powder inhaler product candidates for the treatment of asthma and COPD. The company’s subsidiary, U.S. Compounding, Inc., compounds sterile prescription drugs, and certain nonsterile drugs for patients, animals, hospitals, clinics and surgery centers throughout most of the United States.